Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is among the Most Volatile Stocks. On 6, 2026, TD Cowen upgraded Adaptive ...
Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Management View Chad Robins, Co-Founder, CEO & Chairman, highlighted ...
Hosted on MSN
Adaptive Biotechnologies outlines 39%–42% MRD revenue growth outlook for 2025 with accelerating EMR integration
Chad Robins, CEO & Co-Founder, emphasized "another quarter of strong execution and accelerating momentum across the business," highlighting meaningful wins in profitability and growth for the MRD ...
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment ...
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research ...
In the last three months, 4 analysts have published ratings on Adaptive Biotechnologies (NASDAQ:ADPT), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...
Adaptive Biotechnologies reported a 42% revenue increase in its MRD segment, with a focus on achieving profitability in 2025. Adaptive Biotechnologies Corporation reported its financial results for ...
Adaptive Biotechnologies Corporation and Flatiron Health have announced the integration of Adaptive's clonoSEQ® test for measurable residual disease (MRD) assessment into Flatiron's OncoEMR® ...
SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...
The biotech reported its second-quarter earnings just after market close the previous day. It topped analyst estimates on both the top and bottom lines. The commercial-stage Adaptive booked $58.9 ...
The MarketWatch News Department was not involved in the creation of this content. A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results